Editas Medicine, Inc. (EDIT) Revenue by Segment & Business Profile
CRISPR-based gene editing therapies for serious diseases was 100.0% of Editas Medicine, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EDITEditas Medicine, Inc.Follow EDIT — free
—
Price chart with a free account
- Market cap
- 368.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What the company does
Editas Medicine, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $47.0 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Platform (mRNA / RNAi / gene)
Editas Medicine, Inc. — questions
- What does Editas Medicine, Inc. do?
- Editas Medicine, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $47.0 million as of 2026-06-30.
- How does Editas Medicine, Inc. make money?
- By the lines it reports in its SEC filings: CRISPR-based gene editing therapies for serious diseases 100.0% of revenue.
Every figure on this page comes from Editas Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.